News | January 21, 2022
Biocon consolidated PAT at Rs 187.1 cr. in Q3FY22
Biocon has reported consolidated financial results for the period ended December 31, 2021
Biocon has reported consolidated financial results for the period ended December 31, 2021
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
CliniSys has the proven ability to deliver 100s of millions of medical results a month to enable pandemic-scale population disease surveillance across the globe
He holds nine US patents and has published in multiple peer-reviewed journals and conferences
Narayanan to lead SeQuent through next phase of consolidation and growth
The new collaboration focuses on a class of proteins called transcription factors, which control gene expression and can regulate important cellular processes including cell growth and survival
This surpasses the number of approvals supported in 2020
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
Four-year research collaboration combines Pfizer’s deep experience in global drug development, including programs utilizing messenger RNA (mRNA), lipid nanoparticles (LNP), and gene therapy, with Beam’s leadership in base editing and mRNA/LNP delivery technologies
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
Subscribe To Our Newsletter & Stay Updated
